ArticleBladder cancer (Amsterdam, Netherlands)2023

Economic Outcomes of Hexaminolevulinate Blue-Light Cystoscopy in Non-Muscle Invasive Bladder Cancer: A 5-Year, Medicare-Based Model.

Michael L Creswell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.